ZYXI
Zynex, Inc.
NASDAQ · Healthcare · Medical - Distribution · US
$0.13
+140.38%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 108.2M | 192.4M | 184.3M | 158.2M | 130.3M |
| Cost of Revenue | 30.7M | 39.4M | 38.4M | 32.0M | 26.9M |
| Gross Profit | 77.5M | 152.9M | 146.0M | 126.2M | 103.4M |
| Operating Expenses | |||||
| R&D Expense | 12.0M | — | — | — | 2.6M |
| SG&A Expense | 114.7M | 146.9M | 135.2M | 103.2M | 77.5M |
| General & Admin Expense | 56.2M | 60.4M | 48.5M | 36.1M | 24.4M |
| Selling & Marketing Expense | 58.5M | 86.6M | 86.7M | 67.1M | 53.1M |
| Other Expenses | 18.7M | — | — | — | 949.0K |
| Total Operating Expenses | 145.4M | 146.9M | 135.2M | 103.2M | 81.0M |
| Cost and Expenses | 176.1M | 186.4M | 173.5M | 135.2M | 107.9M |
| Operating Income (EBIT) | (67.9M) | 6.0M | 10.8M | 22.9M | 22.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 3.0M | 2.4M | 1.1M | 440.0K | 95.0K |
| Net Interest Income | (3.0M) | (2.4M) | (1.1M) | (440.0K) | (95.0K) |
| Other Non-Op Income/Expense | (3.0M) | (2.4M) | 1.8M | (740.0K) | (95.0K) |
| Non-Operating Income (excl Interest) | — | (19.0K) | (2.9M) | 300.0K | — |
| EBT (Pre-Tax Income) | (70.9M) | 3.6M | 12.6M | 22.2M | 22.3M |
| Income Tax Expense | 3.0M | 633.0K | 2.8M | 5.2M | 5.2M |
| Bottom Line | |||||
| Net Income | (74.0M) | 3.0M | 9.7M | 17.0M | 17.1M |
| Earnings from Cont. Ops | (74.0M) | 3.0M | 9.7M | 17.0M | 17.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (74.0M) | 3.0M | 9.7M | 17.0M | 17.1M |
| Per Share | |||||
| Basic EPS | ($2.43) | $0.09 | $0.27 | $0.44 | $0.41 |
| Diluted EPS | ($2.43) | $0.09 | $0.27 | $0.44 | $0.40 |
| Revenue Per Share | $3.57 | $6.02 | $5.18 | $4.11 | $3.09 |
| Shares | |||||
| Basic Shares Outstanding | 30.3M | 31.9M | 35.6M | 38.5M | 42.1M |
| Diluted Shares Outstanding | 30.3M | 32.3M | 36.1M | 39.1M | 43.1M |
| Profitability Metrics | |||||
| EBITDA | (64.3M) | 10.8M | 17.9M | 25.8M | 24.7M |
| D&A | 3.6M | 4.8M | 4.2M | 3.1M | 2.3M |
| EBIT | (67.9M) | 6.0M | 13.7M | 22.6M | 22.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025